17.82
price up icon3.66%   0.63
after-market After Hours: 17.64 -0.18 -1.01%
loading
Tonix Pharmaceuticals Holding Corp stock is traded at $17.82, with a volume of 798.90K. It is up +3.66% in the last 24 hours and down -40.14% over the past month. Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$17.19
Open:
$17.05
24h Volume:
798.90K
Relative Volume:
0.50
Market Cap:
$102.89M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-1.5826
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
+13.43%
1M Performance:
-40.14%
6M Performance:
+7.67%
1Y Performance:
-96.52%
1-Day Range:
Value
$16.83
$18.74
1-Week Range:
Value
$14.33
$18.74
52-Week Range:
Value
$7.31
$672.00

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Name
Name
Tonix Pharmaceuticals Holding Corp
Name
Phone
212-980-9155
Name
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Name
Employee
81
Name
Twitter
@TONIXPharma
Name
Next Earnings Date
2025-03-17
Name
Latest SEC Filings
Name
TNXP's Discussions on Twitter

Compare TNXP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TNXP
Tonix Pharmaceuticals Holding Corp
17.82 102.89M 0 -121.02M -114.09M -11.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-18-22 Initiated Noble Capital Markets Outperform
Apr-18-19 Upgrade ROTH Capital Neutral → Buy
Aug-18-17 Upgrade ROTH Capital Neutral → Buy
Sep-07-16 Downgrade ROTH Capital Buy → Neutral
Feb-17-16 Reiterated Oppenheimer Outperform
Nov-04-15 Initiated Cantor Fitzgerald Buy
Jun-12-15 Initiated Oppenheimer Outperform
Feb-17-15 Reiterated ROTH Capital Buy
Sep-29-14 Reiterated ROTH Capital Buy
View All

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News

pulisher
05:03 AM

Tonix Pharmaceuticals Holding CorpDiscontinued Enrollment And Terminated Phase 2 Catalyst StudySEC Filing - marketscreener.com

05:03 AM
pulisher
01:27 AM

Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data - citybuzz -

01:27 AM
pulisher
Apr 24, 2025

Tonix reports promising results for mpox vaccine TNX-801 By Investing.com - Investing.com South Africa

Apr 24, 2025
pulisher
Apr 24, 2025

Tonix reports promising results for mpox vaccine TNX-801 - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Tonix Pharmaceuticals (TNXP) Unveils Promising Results for Single-Dose Mpox Vaccine | TNXP Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 | TNXP Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 - The Manila Times

Apr 24, 2025
pulisher
Apr 24, 2025

Tonix Pharmaceuticals Presented Data on Potential Mpox - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

Single-Dose Mpox Vaccine Breakthrough: Complete Protection for Immunocompromised Patients in Latest Trial - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Tonix Pharma Presents Promising Vaccine Data at Congress - TipRanks

Apr 24, 2025
pulisher
Apr 23, 2025

Tonix Pharmaceuticals (TNXP) Falls Despite Market Upturn - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Tonix Pharmaceuticals (TNXP) to Present at World Vaccine Congress - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

When the Price of (TNXP) Talks, People Listen - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 16, 2025

Tonix Pharmaceuticals Announces Oral Presentation And Panel Participation At The World Vaccine Congress Washington 2025 - marketscreener.com

Apr 16, 2025
pulisher
Apr 16, 2025

Tonix Pharmaceuticals Announces Oral Presentation and Panel - GlobeNewswire

Apr 16, 2025
pulisher
Apr 16, 2025

Major Breakthrough: Tonix Unveils Single-Dose Mpox Vaccine Data at Leading Global Conference - Stock Titan

Apr 16, 2025
pulisher
Apr 12, 2025

Why Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday? - MSN

Apr 12, 2025
pulisher
Apr 09, 2025

Tonix and Makana partner on xenotransplantation research By Investing.com - Investing.com India

Apr 09, 2025
pulisher
Apr 09, 2025

Tonix Pharmaceuticals and Makana Therapeutics Announce Collabora - GuruFocus

Apr 09, 2025
pulisher
Apr 09, 2025

Tonix and Makana partner on xenotransplantation research - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

Tonix Pharmaceuticals and Makana Therapeutics Announce - GlobeNewswire

Apr 09, 2025
pulisher
Apr 09, 2025

Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix'S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana'S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Revolutionary Xenotransplantation Breakthrough: Tonix and Makana Join Forces to Combat Organ Failure - Stock Titan

Apr 09, 2025
pulisher
Apr 08, 2025

Tonix Pharmaceuticals launches :TONIX ONE™ A digital breakthrough in migraine management - Proactive financial news

Apr 08, 2025
pulisher
Apr 07, 2025

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting - GlobeNewswire

Apr 07, 2025
pulisher
Apr 07, 2025

Game-Changing Fibromyalgia Treatment Achieves Phase 3 Success, FDA Decision Looms - Stock Titan

Apr 07, 2025
pulisher
Apr 07, 2025

(TNXP) Investment Analysis - news.stocktradersdaily.com

Apr 07, 2025
pulisher
Apr 04, 2025

Peering Into Tonix Pharmaceuticals's Recent Short Interest - Benzinga

Apr 04, 2025
pulisher
Apr 03, 2025

TNXP: No AdCom Required for TNX-102 SL NDA… - Yahoo Finance

Apr 03, 2025
pulisher
Apr 02, 2025

Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

Tonix Pharmaceuticals Reveals 5 Major Catalysts: FDA Decision, DoD Contract, and Breakthrough Therapies - Stock Titan

Apr 02, 2025
pulisher
Apr 01, 2025

Tonix Pharmaceuticals launches migraine management platform By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Tonix Pharmaceuticals Launches TONIX ONE™, a - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Tonix Pharma stock rises following TONIX ONE launch By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Tonix Pharma stock rises following TONIX ONE launch - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Tonix Pharmaceuticals launches migraine management platform - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Game-Changing Digital Platform Transforms How Patients Track and Treat Migraines - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Lat - PharmiWeb.com

Mar 31, 2025
pulisher
Mar 31, 2025

Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year - ACCESS Newswire

Mar 31, 2025
pulisher
Mar 31, 2025

Revolutionary Non-Opioid Pain Drug Could Transform Fibromyalgia Treatment by 2025 - Stock Titan

Mar 31, 2025
pulisher
Mar 29, 2025

New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - Bluefield Daily Telegraph

Mar 29, 2025
pulisher
Mar 27, 2025

(TNXP) Long Term Investment Analysis - Stock Traders Daily

Mar 27, 2025
pulisher
Mar 27, 2025

Tonix Pharmaceuticals Announces Presentation at the - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Fast-Tracked Fibromyalgia Treatment: Tonix Showcases Breakthrough Pain Drug Data Before FDA Decision - StockTitan

Mar 27, 2025
pulisher
Mar 26, 2025

2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years - Seeking Alpha

Mar 26, 2025
pulisher
Mar 25, 2025

Noble Capital maintains Outperform on Tonix Pharma, $70 target By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Noble Capital maintains Outperform on Tonix Pharma, $70 target - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic (TNXP) - Seeking Alpha

Mar 25, 2025
pulisher
Mar 25, 2025

Pharma Frenzy: Volatility Ignites Biotech Sector - Benzinga

Mar 25, 2025

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):